Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors

Online download statistics by month:

Online download statistics by month: February 2024 to September 2025

	Abstract	Full	Pdf
Feb 2024	1441	1451	647
Mar 2024	454	460	287
Apr 2024	325	326	177
May 2024	416	418	149
Jun 2024	266	268	123
Jul 2024	256	257	132
Aug 2024	225	223	92
Sep 2024	223	225	133
Oct 2024	223	223	101
Nov 2024	311	313	153
Dec 2024	275	278	124
Jan 2025	279	279	148
Feb 2025	343	345	165
Mar 2025	288	288	186
Apr 2025	306	307	146
May 2025	255	256	167
Jun 2025	184	184	109
Jul 2025	1	1	0
Aug 2025	1	1	0
Sep 2025	1	0	0
Total	6073	6103	3039